Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 627 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study

Gupta Sunil, Shaikh Shehla, Joshi Pooja, Bhure Shraddha, Suvarna Viraj

Year : 2017| Volume: 21| Issue : 2 | Page no: 286-292

   This article has been cited by
1 Sodium-Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus Without Established Cardiovascular Disease: Do They Have a Role in Primary Prevention?
Dr Shailaja Kale,Dr Abd A Tahrani
Metabolism Open. 2021; : 100082
[Pubmed]  [Google Scholar] [DOI]
2 RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Rajeev Chawla,S. V. Madhu,B. M. Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra
International Journal of Diabetes in Developing Countries. 2020; 40(S1): 1
[Pubmed]  [Google Scholar] [DOI]
3 Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study
Manash P Baruah,Sanjay Kalra
European Endocrinology. 2019; 15(2): 113
[Pubmed]  [Google Scholar] [DOI]
4 Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Jennifer R Donnan,Catherine A Grandy,Eugene Chibrikov,Carlo A Marra,Kris Aubrey-Bassler,Karissa Johnston,Michelle Swab,Jenna Hache,Daniel Curnew,Hai Nguyen,John-Michael Gamble
BMJ Open. 2019; 9(1): e022577
[Pubmed]  [Google Scholar] [DOI]
5 Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
Awadhesh Kumar Singh,Ambika G. Unnikrishnan,Abdul H. Zargar,Ajay Kumar,Ashok K. Das,Banshi Saboo,Binayak Sinha,Kalyan Kumar Gangopadhyay,Pradeep G. Talwalkar,Samit Ghosal,Sanjay Kalra,Shashank Joshi,Surendra Kumar Sharma,Usha Sriram,Viswanathan Mohan
Diabetes Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
6 Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis
Hongmei Wang,Jiadan Yang,Xi Chen,Feng Qiu,Juan Li
Clinical Therapeutics. 2019;
[Pubmed]  [Google Scholar] [DOI]
7 Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
Habib Yaribeygi,Stephen L. Atkin,Amirhossein Sahebkar
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(2): 1679
[Pubmed]  [Google Scholar] [DOI]
Pattanaik S.R
Journal of Evidence Based Medicine and Healthcare. 2018; 4(14): 1226
[Pubmed]  [Google Scholar] [DOI]
9 Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Xia Dai,Zu-chun Luo,Lu Zhai,Wen-piao Zhao,Feng Huang
Diabetes Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]


Read this article